UBS lowered the firm’s price target on enGene (ENGN) to $2 from $9 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Leerink downgraded enGene to Market Perform following LEGEND update
- enGene downgraded to Perform from Outperform at Oppenheimer
- enGene downgraded to Market Perform from Outperform at Leerink
- Leland Gershell Reiterates Hold on enGene as LEGEND Trial Efficacy Declines and Withdraws Sales Forecasts and Price Target Pending Greater Clarity
- enGene downgraded to Outperform from Strong Buy at Raymond James